# US 2011/0087043 A1 · Site-Specific Inhibitors of Histone Methyltransferase (HMTASE) and Process of Preparation Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0087043 A1
- Document ID: US20110087043A1
- Status: Published application
- Kind: A1
- Application number: 12/905,927
- Filed: 2010-10-15
- Published: 2011-04-14
- Earliest claimed: 2006-06-27
- Assignees: Jawaharlal Nehru Centre for Advanced Scientific Research
- Inventors: Tapas Kumar Kundu; Ruthrotha Selvi Bharatha Vikru; Hari Kishore Annavarapu; Mantelingu Kempegowda
- Web page: https://patentgrep.com/patent/US20110087043A1

## CPC

- C07C 67/56: by solid-liquid treatment; by chemisorption
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of structural formula I as site-specific inhibitors of histone methyltransferase, where R1 and R1 is —OCH3 or —OH, R2 and R2 is —OH or —OAc; a process of isolating compound of structural formula Ia, where R1 and R1 is —OCH3, R2 and R2 is —OH; a process of preparation of compound of structural formula Ib, where R1 and R1 is —OCH3, R2 and R2 is —OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is —OH, R2 and R2 is —OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and/or disease conditions in a subject in need thereof.

## Claims

### Claim 1

Use of compounds of structural formula I for manufacture of a medicament for management of cancer and for disease conditions in a subject in need thereof.

### Claim 2 (depends on 1)

The use as claimed in claim 1, wherein the compounds are inhibitors of histone methyltransferase.

### Claim 3 (depends on 2)

The use as claimed in claim 2, wherein the histone methyltransferase is arginine methyltransferase, preferably CARM1.

### Claim 4 (depends on 1)

The use as claimed in claim 1, wherein the nature of inhibition of compound is uncompetitive.

### Claim 5 (depends on 1)

The use as claimed in claim 1, wherein the compounds are antiproliferative and antiangiogenic in nature.

### Claim 6 (depends on 1)

The use as claimed in claim 1, wherein the compounds modulate the transcriptional activation of p53 responsive genes.

### Claim 7 (depends on 1)

The use as claimed in claim 1, wherein the subject is animal including human being.
